ArticleJournal of managed care & specialty pharmacy2025

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.

Santosh Gautam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.